Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reporte...
Main Authors: | Hampig Raphael Kourie, Joelle Antoun, Elie El Rassy, Marc Rassy, Claude Sader-Ghorra, Joseph Kattan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-09-01
|
Series: | Journal of Bone Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137415300105 |
Similar Items
-
Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology
by: Aya Alsalih, et al.
Published: (2021-07-01) -
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
by: Vittorio Fusco, et al.
Published: (2018-09-01) -
ZOLEDRONATE-ASSOCIATED RECURRENCE OF OSTEONECROSIS OF JAWS
by: Rosen Tsolov, et al.
Published: (2020-10-01) -
Bisphosphonate-related osteonecrosis of the jaws: Report of two cases with breast cancer, a dental concern and review of the literature
by: Ahmet Ercan Şekerci, et al.
Published: (2012-07-01) -
Medication-related osteonecrosis of the jaw in a patient with multiple myeloma
by: Nupur Bhardwaj, et al.
Published: (2015-01-01)